Background In the phase 1–2 portion of an adaptive trial, REGEN-COV, a combination of the
monoclonal antibodies casirivimab and imdevimab, reduced the viral load and number of …

Background Recent data suggest that complications and death from coronavirus disease
2019 (Covid-19) may be related to high viral loads. Methods In this ongoing, double-blind, …

Background A range of safe and effective vaccines against SARS CoV 2 are needed to
address the COVID 19 pandemic. We aimed to assess the safety and efficacy of the COVID-19 …

Background REGN3470-3471-3479 is a co-formulated cocktail of three human monoclonal
antibodies targeting three non-overlapping epitopes on Ebola virus. We investigated safety, …

Background Open-label platform trials and a prospective meta-analysis suggest efficacy of
anti–interleukin (IL)-6R therapies in hospitalized patients with coronavirus disease 2019 (…

Background REGEN-COV antibody cocktail (casirivimab with imdevimab) rapidly reduced
viral load and decreased medically-attended visits in the phase 1/2 portion of this trial; REGEN…

Background The open-label RECOVERY study reported improved survival in hospitalized,
SARS-CoV-2 seronegative patients treated with casirivimab and imdevimab (CAS + IMD). …

BACKGROUND Sarilumab (anti-interleukin-6 receptor-α monoclonal antibody) may attenuate
the inflammatory response in Covid-19. METHODS We performed an adaptive, phase 2/3, …

… of Johnson & Johnson; Brian Dreyfus is an employee of Bristol-Myers Squibb Company;
Anju Garg is an employee of Sanofi; Marian Habib is an employee of Allergan; Romana Hosain …

Background Hospitalized patients with Covid-19 experience high mortality rates, ranging
from 10-30%. Casirivimab and imdevimab (REGEN-COV ® ) is authorized in various …